Compare NICE & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | ALKS |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.5B |
| IPO Year | N/A | 2012 |
| Metric | NICE | ALKS |
|---|---|---|
| Price | $119.24 | $28.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $158.85 | $43.43 |
| AVG Volume (30 Days) | 739.9K | ★ 1.8M |
| Earning Date | 02-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $10.21 | $24.06 |
| Revenue Next Year | $9.70 | $4.53 |
| P/E Ratio | ★ $11.21 | $19.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $94.65 | $25.17 |
| 52 Week High | $180.61 | $36.32 |
| Indicator | NICE | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 39.48 |
| Support Level | $104.02 | $27.48 |
| Resistance Level | $136.93 | $28.75 |
| Average True Range (ATR) | 4.11 | 0.92 |
| MACD | -0.61 | -0.06 |
| Stochastic Oscillator | 25.18 | 37.46 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.